Health and Fitness Health and Fitness
Tue, December 7, 2010
[ Tue, Dec 07th 2010 ] - Market Wire
Pr©sentation de donn©es sur le traitement au RE .. y©lome multiple, ©valuant les taux de survie av
[ Tue, Dec 07th 2010 ] - Market Wire
Gegevens uit drie presentaties evalueren klinisch .. n eerder behandeld meervoudig myeloom tijdens ASH
Mon, December 6, 2010
[ Mon, Dec 06th 2010 ] - Market Wire
Law Office of Brodsky & Smith, LLC Announces Inve .. gation of Caraco Pharmaceutical Laboratories Ltd.
[ Mon, Dec 06th 2010 ] - Market Wire
Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Genoptix, Inc.
[ Mon, Dec 06th 2010 ] - Market Wire
Positron Receives Highest Mark of Compliance from Nuclear Regulatory Commission
[ Mon, Dec 06th 2010 ] - Market Wire
YM BioSciences Reports Positive Interim Data Incl .. onse from Phase I/II Trial of JAK1/JaK2 Inhibitor
[ Mon, Dec 06th 2010 ] - Market Wire
Long-Term Follow-Up Data from Phase 2 Study Show .. uces Durable Remissions in Patients with Acute Ly
[ Mon, Dec 06th 2010 ] - Market Wire
Forest Laboratories and Gruenenthal Enter Into Li .. elopment and Commercialization of Novel Analgesic
[ Mon, Dec 06th 2010 ] - Market Wire
The Law Firm of Levi & Korsinsky, LLP Launches an .. ble Breaches of Fiduciary Duty by the Board of Ca
[ Mon, Dec 06th 2010 ] - Market Wire
Valeant Pharmaceuticals International, GlaxoSmithKline, Pfizer, UCB Pharma and Johnson & Johnson
[ Mon, Dec 06th 2010 ] - Market Wire
Klinische Daten zur Evaluierung von oral verabrei .. Rituximab oder nach einer Rituximab-Kombinationst
[ Mon, Dec 06th 2010 ] - Market Wire
Micrometa?s Blinatumomab Produces High Objective .. trum of Relapsed Non-Hodgkina?s Lymphoma Patients
[ Mon, Dec 06th 2010 ] - Market Wire
Geron Presents Clinical Data on Its Telomerase Va .. t the 2010 American Society of Hematology Meeting
[ Mon, Dec 06th 2010 ] - Market Wire
REPEAT/ ARIADa?s Ponatinib Shows Clinical Evidenc .. emic Activity in Patients with Drug-Resistant CML
[ Mon, Dec 06th 2010 ] - Market Wire
Incyte Presents Positive Long-Term Results from O .. 18424 in Advanced Polycythemia Vera (PV) and Esse
[ Mon, Dec 06th 2010 ] - Market Wire
New Studies Support Therapeutic Potential of Comp .. Discovered Target for Multiple Myeloma Treatment
[ Mon, Dec 06th 2010 ] - Market Wire
Cubist Pharmaceuticals Files Citizen Petition with Food and Drug Administration
[ Mon, Dec 06th 2010 ] - Market Wire
Biogen Idec e Swedish Orphan Biovitrum annunciano .. lla proteina di fusione ricombinante a lungo term
[ Mon, Dec 06th 2010 ] - Market Wire
ZIOPHARM Presents New Darinaparsin Preclinical Lymphoma Data at ASH Annual Meeting
[ Mon, Dec 06th 2010 ] - Market Wire
Biogen Idec et Swedish Orphan Biovitrum annoncent .. patient dans le cadre da?un essai mondial da?homo
[ Mon, Dec 06th 2010 ] - Market Wire
Biogen Idec und Swedish Orphan Biovitrum melden e .. enden rekombinanten Faktor-VIII-Fc-Fusionsprotein
[ Mon, Dec 06th 2010 ] - Market Wire
Seattle Genetics and Millennium Report Positive D .. ntuximab Vedotin (SGN-35) in Relapsed or Refracto
[ Mon, Dec 06th 2010 ] - Market Wire
Phase III Study Showed Rituxan® for Initial Use .. yed the Need for Additional Therapy in People wit
[ Mon, Dec 06th 2010 ] - Market Wire
Updated Results from FOLOTYN® Phase 1 Dose Findi .. in Relapsed or Refractory Cutaneous T-Cell Lymph
[ Mon, Dec 06th 2010 ] - Market Wire
Alexion Reports Results from First Clinical Trial .. Cancer Antibody Samalizumab at ASH Annual Meeting
[ Mon, Dec 06th 2010 ] - Market Wire
Continuous Treatment with REVLIMID® for Patients .. ng Autologous Stem Cell Transplant Evaluated by I
[ Mon, Dec 06th 2010 ] - Market Wire
New Clinical Data Evaluating ISTODAX® in Pivotal .. r Patients with Peripheral T-Cell Lymphoma (PTCL)
[ Mon, Dec 06th 2010 ] - Market Wire
Covidien Succeeds in Patent Actions against Five Companies
[ Mon, Dec 06th 2010 ] - Market Wire
Covidien obtient gain de cause dans le cadre d'actions en contrefaon contre cinq soci©t©s
[ Mon, Dec 06th 2010 ] - Market Wire
Covidien vince le cause di contestazione della violazione di brevetto contro cinque societ

Covidien vince le cause di contestazione della violazione di brevetto contro cinque societ


Published on 2010-12-06 03:21:07 - Market Wire
  Print publication without navigation


NEW HAVEN, Conn.--([ BUSINESS WIRE ])--Covidien (NYSE: COV), societ leader mondiale nella fornitura di prodotti sanitari, ha annunciato oggi che un tribunale tedesco ha aggiudicato le ingiunzioni preliminari dell'azienda contro J. ZH. FA. Panther Healthcare Medical Equipment Co. Ltd. , WuXi Shenkang Medical Instrument Equipment Co. Ltd. e altre tre aziende di dispositivi medici accusate di contraffazione del design dei prodotti di sutura chirurgica di Covidien e di violazione di un brevetto di Covidien. Quattro delle aziende di dispositivi medici hanno sede in Cina e una nel Regno Unito. Nel corso di procedure parallele, le autorit doganali tedesche hanno anche confiscato a ognuna delle cinque aziende i prodotti di sutura chirurgica oggetto della violazione.

Il testo originale del presente annuncio, redatto nella lingua di partenza, la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit del lettore e devono rinviare al testo in lingua originale, che l'unico giuridicamente valido.

Contributing Sources